The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Big Pharma's Interest in Vaccine Products on Rise
Pipeline Gap Could Be Remedied by Recent Innovations and Fruitful Biotechnology Partnerships
- Big pharma faces a patent cliff in 2012 when around $90 billion in revenue could be lost to generics. The companies that are going to weather this storm have to look at other revenue streams. Vaccine development is gaining a lot of attention because it has an attractive adjacency ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.